Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

TY - JOUR

T1 - Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

AU - Nooka, Ajay K.

AU - Kaufman, Jonathan L.

AU - Rodriguez, Cesar

AU - Jakubowiak, Andrzej

AU - Efebera, Yvonne

AU - Reeves, Brandi

AU - Wildes, Tanya

AU - Holstein, Sarah A.

AU - Anderson, Larry D.

AU - Badros, Ashraf

AU - Shune, Leyla

AU - Chari, Ajai

AU - Pei, Huiling

AU - Cortoos, Annelore

AU - Patel, Sharmila

AU - Bartlett, J. Blake

AU - Vermeulen, Jessica

AU - Lin, Thomas S.

AU - Richardson, Paul G.

AU - Voorhees, Peter

N1 - Funding Information: AKN served as a consultant for, received honoraria from, and received research funding from Janssen, Amgen, Takeda, Sanofi, Karyopharm Therapeutics, Bristol Myers Squibb, Oncopeptides, Adaptive, and Spectrum. JLK has served as a consultant for, received honoraria from, or received research funding from AbbVie, Amgen, Bristol Myers Squibb, Fortis Therapeutics, Heidelberg Pharma, Janssen, Novartis, Roche/Genentech, Sutro Biopharma, Takeda, and Tecnopharma; and has served as a member on the board of directors or advisory committees for Incyte and TG Therapeutics. CR has served as an advisor or speaker for Amgen, Bristol Myers Squibb, Janssen, Karyopharm, and Takeda. AJ held membership on an entity’s board of directors or served on advisory committees for Sanofi, Karyopharm, Janssen, GlaxoSmithKline, Amgen, AbbVie, Bristol Myers Squibb, Gracell, and Celgene. YE has received honoraria from Janssen, GlaxoSmithKline, Takeda, Oncopeptide, Alnylam, and Sanofi; served on a speakers bureau and/or as an advisor for Oncopeptide, Sanofi, Janssen, Takeda, Alnylam, and GlaxoSmithKline; and received research funding from Bristol Myers Squibb/Celgene. BR has received honoraria from Takeda and Incyte; served on a speakers bureau for Bristol Myers Squibb; and provided consultancy for and received honoraria from Pharma Essentia. TW has served as a consultant for Janssen, Carevive, Sanofi, and Seattle Genetics. SAH held membership on an entity’s board of directors or served on an advisory committee for Oncopeptides, Celgene, and Takeda; received honoraria from Celgene, Genentech, GlaxoSmithKline, Janssen, Secura Bio, Sorrento, and Takeda; and received research funding from Oncopeptides. LDA has served as a consultant for, received research funding or honoraria from, held membership on an entity’s board of directors or served on advisory committees for Amgen, Bristol Myers Squibb, Celgene, Janssen, GlaxoSmithKline, Janssen, Karyopharm, AbbVie, Prothena, and Oncopeptides. AB has received research funding from Bristol Myers Squibb and GlaxoSmithKline. LS has nothing to disclose. ACh held membership on an entity’s board of directors, or participated on advisory committees for AbbVie, Amgen, Bristol Myers Squibb/Celgene, Genentech, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Sanofi, Seattle Genetics, Secura Bio, Antengene, and Shattuck Labs; received research funding from Amgen, Bristol Myers Squibb/Celgene, Janssen, Seattle Genetics, Pharmacyclics, and Takeda/Millennium; and acted as a consultant for Amgen, AbbVie, Antengene, Bristol Myers Squibb/Celgene, Genentech, GlaxoSmithKline, Janssen, Karyopharm, Novartis, Sanofi, Secura Bio, Shattuck Labs, and Takeda/Millennium. HP, ACo, BB, and JV are current employees and stock shareholders of Janssen. SP is a current employee of Janssen. TSL is a current employee and stock shareholder of Janssen and holds stock in GlaxoSmithKline. PGR has received research funding from Celgene/Bristol Myers Squibb, Karyopharm, Oncopeptides, and Takeda; and has served on advisory committees for AstraZeneca, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, and Secura Bio. PV has served as a consultant for, received honoraria from, or served as an advisory board member for AbbVie, Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Novartis, Oncopeptides, Pfizer, Sanofi, and Secura Bio. Funding Information: We acknowledge the patients and investigators who participated in this study, in addition to the staff members at the study sites, the Data Review and Safety Monitoring Committees, Alliance Foundation Trials (AFT; https://acknowledgments.alliancefound.org [study AFT-29]), and the Janssen Team. We also acknowledge Daniela Hoehn, Yana Lutska, and Padma Bobba for their contributions to this study. This work was funded by Janssen Oncology. The study was sponsored by Janssen Oncology and designed in partnership with AFT. Editorial and medical writing support were provided by Laura Weber, PhD, of Cello Health Communications/MedErgy, and were funded by Janssen Global Services, LLC. Funding Information: We acknowledge the patients and investigators who participated in this study, in addition to the staff members at the study sites, the Data Review and Safety Monitoring Committees, Alliance Foundation Trials (AFT; https://acknowledgments.alliancefound.org [study AFT-29]), and the Janssen Team. We also acknowledge Daniela Hoehn, Yana Lutska, and Padma Bobba for their contributions to this study. This work was funded by Janssen Oncology. The study was sponsored by Janssen Oncology and designed in partnership with AFT. Editorial and medical writing support were provided by Laura Weber, PhD, of Cello Health Communications/MedErgy, and were funded by Janssen Global Services, LLC.

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85128316769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128316769&partnerID=8YFLogxK

U2 - 10.1038/s41408-022-00653-1

DO - 10.1038/s41408-022-00653-1

M3 - Letter

C2 - 35418120

AN - SCOPUS:85128316769

VL - 12

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 4

M1 - 63

ER -